特发性门静脉高压
特发性门静脉高压(IPH)是一种在无可识别病因(如肝硬化)情况下出现临床门静脉高压的罕见疾病。实验室检查常显示肝功能保留,并因脾肿大而出现贫血、白细胞减少和血小板减少。肝活检被认为是排除其他门静脉高压病因(主要是肝硬化)的必要手段,组织学可能仅显示轻微或轻度改变,确诊常需专家病理学家和高品质标本。
要点
- IPH表现为门静脉高压但肝功能保留,伴脾肿大所致贫血、白细胞减少和血小板减少。
- 肝活检被认为是排除肝硬化等其他病因的必要手段,确诊常需专家病理学家与高质量标本。
- 最常见临床表现为静脉曲张出血,腹水初期罕见但随访中偶可出现。
核心结论
- IPH患者长期预后优于肝硬化患者,腹水和基础疾病是重要预后因素。
- 改变疾病自然病程的治疗仍是未满足的需求,管理常限于控制门静脉高压相关并发症。
研究设计与样本
- 综述,检索范围未报告。
主要发现
- 实验室检查常显示肝功能保留,伴贫血、白细胞减少和血小板减少。
- 影像学显示门静脉高压征象,而肝脏硬度和门静脉压力值通常正常或轻度升高。
- 肝组织学可能仅显示轻微或轻度改变,确诊常需专家病理学家和高品质标本。
- 最常见临床表现为静脉曲张出血,腹水初期罕见但随访中偶可出现。
- 与IPH相关的典型组织学表现也见于无门静脉高压的患者,可能代表疾病早期阶段。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Idiopathic portal hypertension (IPH) is a rare disorder characterized by clinical portal hypertension in the absence of a recognizable cause such as cirrhosis. Laboratory tests often reveal a preserved liver function with anemia, leukopenia, and thrombocytopenia due to splenomegaly. Imaging studies reveal signs of portal hypertension, whereas liver stiffness and portal pressure values are usually normal or slightly elevated. Liver biopsy is considered mandatory in order to rule out other causes of portal hypertension, mainly cirrhosis. Liver histology may only show subtle or mild changes, and the definite diagnosis of IPH often requires an expert pathologist and a high-quality specimen. The most frequent clinical presentation is variceal bleeding. Ascites is rarely observed initially, although it may occasionally appear during follow-up. Typical histological findings associated with IPH have been described in patients without portal hypertension, probably representing early stages of the disease. Although the pathophysiology of this entity remains largely unknown, it is frequently associated with underlying immunological disorders, bacterial infections, trace metal poisoning, medications, liver circulatory disturbances, and thrombotic events. The long-term prognosis of patients with IPH, where ascites and the underlying condition are important prognostic factors, is better than in patients with cirrhosis. Treatments that modify the natural history of the disease remain an unmet need, and management of IPH is frequently restricted to control of portal hypertension-related complications.
引用
- Hernández-Gea V, Baiges A, Turon F, et al. Idiopathic Portal Hypertension. Hepatology. 2018. PMID: 30066417. doi:10.1002/hep.30132
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。